[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"generalized-anxiety-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:generalized-anxiety-disorder":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,49,0,25,[9,44,67,100,128,152,176,217,252,285,307,329,350,382,412,454,477,500,529,549,568,589,606,625,651],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100630590","phase-2-re104-safety-and-efficacy-study-in-generalized-anxiety-disorder-100630590",false,"NCT07489651","RE104 Safety and Efficacy Study in Generalized Anxiety Disorder","A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Generalized Anxiety Disorder","Inclusion Criteria:\n\n* Has Generalized Anxiety Disorder as defined by DSM-5-TR\n* If female is not pregnant or planning to become pregnant. If male is not planning to make a partner pregnant.\n* Is willing and able to comply with the conditions and requirements of the study\n\nExclusion Criteria:\n\n* Has a significant risk of suicide\n* Has an active or medical history of bipolar disorder, schizophrenia, schizoaffective disorder, psychotic disorder and\u002For borderline personality disorder, or first-degree family history of psychosis or bipolar disorder\n* Has other concurrent psychiatric disorders that is the primary disorder.\n* Has other medically significant conditions rendering unsuitability for the study\n* Has used or will need to use prohibited medications or therapies\n* Has a known sensitivity or intolerance to study intervention or potential rescue medications","ALL","18 Years","74 Years",{"count":21,"type":22},64,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.",[28],"Generalized Anxiety Disorder",[30],"GAD","RECRUITING","2026-06-23",{"date":34,"type":35},"2026-06-26","ACTUAL",{"date":37,"type":35},"2026-04-20",{"date":39,"type":22},"2027-04",{"name":41,"class":42},"Reunion Neuroscience Inc","INDUSTRY",22,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":66},"100629751","phase-2-a-phase-2a-efficacy-safety-tolerability-and-pk-study-of-syt-510-in-participants-with-generalized-anxiety-disorder-100629751","NCT07478744","A Phase 2a Efficacy, Safety, Tolerability, and PK Study of SYT-510 in Participants With Generalized Anxiety Disorder","A Study Investigating the Efficacy, Safety, Tolerability, and Pharmacokinetics of a Single Dose of SYT-510 in Participants Who Meet DSM-5 Diagnostic Criteria for Generalized Anxiety Disorder","Inclusion Criteria:\n\n1. Males or females aged 18 to 55 years old (inclusive) at the date of signing the ICF.\n2. Participants who are currently unmedicated and meet the criteria for GAD as defined in the DSM-5 by using the MINI.\n3. Participants must be right-handed.\n4. BMI between 18 and 30 kg\u002Fm2, inclusive, at Screening and a minimum weight of 50 kg.\n5. Contraception use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n6. Participants must agree not to donate sperm or ova from the time of the first administration of study drug (T1, D2) until 3 months after the participant's last visit.\n7. Ability to provide written, personally signed, and dated informed consent to participate in the study, in accordance with the current version of the ICH GCP Guideline E6 and applicable regulations, before completing any study-related procedures.\n8. Have an understanding, ability, and willingness to fully comply with study procedures as detailed in the Study Protocol and ICF.\n\nExclusion Criteria:\n\n1. Current or past diseases (e.g., cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematologic, neurologic, endocrine, immunologic, rheumatologic, dermatologic or other conditions) that may interfere with the execution of the conduct of the study, as per the Investigator's judgment.\n2. Participants with current or recurrent disease or treatment that can interfere with the absorption, metabolism, and elimination of SYT-510. Examples include participants with partial gastrostomy or impaired renal functions.\n3. Participants with significant learning difficulties, uncorrected visual and auditory problems and history of dyslexia.\n4. Participants with a current DSM-5 diagnosis of major depressive disorders or severe depressive symptoms determined by MADRS score \\> 20.\n5. Substance use disorder within the past 6 months before Screening.\n6. Any primary diagnosis other than GAD e.g., bipolar disorder, obsessive compulsive disorder, PTSD, psychotic disorder, cognitive impairment, or pervasive development disorder.\n7. Any psychotic features, including dementia or delirium.\n8. Experienced suicidal ideation with some intent to act within the 6 months preceding screening or any history of suicidal behavior.\n9. Other current or relevant history of physical, neurological or psychiatric illness that may require treatment (e.g., any history of epilepsy).\n10. Participants with contraindications for MRI.\n11. Conditions that make the participant unlikely to fully comply with the requirements of the study or complete the study, or any condition that presents undue risk from the study drug or study procedures.\n12. Positive test for HBsAg, hepatitis C virus antibody, or human immunodeficiency virus antibody at Screening.\n13. Active systemic bacterial, viral, or fungal infection within 14 days prior to dosing on T1, D2 or presence of fever (confirmed body temperature \\> 38 ºC) within 14 days prior to dosing on T1, D2.\n\n    Diagnostic Assessments\n14. Laboratory parameters outside of the laboratory normal range (hematology, biochemistry, coagulation, urinalysis), unless deemed NCS by the Investigator.\n15. Has vital signs outside of the following normal range at Screening or Baseline, unless considered NCS by the Investigator: supine SBP 90-140 mmHg, supine DBP 50-90 mmHg, supine PR 40-100 bpm.\n16. Has any clinically significant abnormalities in rhythm, conduction or morphology of resting ECG or clinically important abnormalities that may interfere with the interpretation of QTc interval changes, or values outside of the normal range, unless considered NCS by the Investigator.\n17. Positive test results for alcohol or drugs of abuse at Screening or Baseline. Prior\u002FConcomitant Therapies\n18. Has used any prescription medication (excluding hormonal therapy for postmenopausal women or contraception for WOCBP) within 30 days prior to Screening and any medication for the treatment of anxiety within 6 months prior to screening.\n19. Consumption of herbal remedies or dietary supplements which may interact with the study drug (for example containing St. John's Wort) in the 30 days prior to first dose and until the end of the study.\n20. Use of cannabis, tetrahydrocannabinol or cannabidiol containing products in the 28 days before the Study T1, D2.\n21. Participants who have received a live vaccine within 30 days prior to the first dose administration or who plan to receive a live vaccine during the study period.\n\n    Prior \u002F Concurrent Clinical Study Experience\n22. Treatment with an investigational drug within 90 days or 5 half-lives preceding the first dose of trial intervention (or as determined by the local requirement, whichever is the longer) or will start any other investigational product or device study within 90 days after last study drug administration.\n\n    Other Exclusion Criteria\n23. Known or suspected intolerance or hypersensitivity to the investigational product, any closely related compound, or any of the stated ingredients.\n24. History of significant allergic reactions (anaphylaxis, angioedema) to any product (food, pharmaceutical, etc.).\n25. Donation of blood or blood products within 90 days, or plasma within 7 days prior to study drug administration on T1, D2.\n26. Underwent general anesthesia in the 30 days prior to study drug administration on T1, D2.\n27. Nicotine consumption (in any form) equivalent to \\> 5 cigarettes or vapes per week.\n28. Weekly intake of more than 14 units of alcohol.","55 Years",{"count":53,"type":22},24,[25],"This is a single dose study to investigate the efficacy, safety, tolerability and the PK, of SYT-510 in participants who meet diagnostic criteria of GAD. This study represents an evaluation of the effects of SYT-510 in participants meeting DSM-5 GAD diagnostic criteria. As a single dose study, it is designed to evaluate the efficacy of SYT-510 on neurobiological and behavioral markers associated with anxiety and will inform the design of future clinical trials in anxiety disorders. By integrating efficacy \u002F PD, safety, tolerability, and PK measures within the same study framework, the study enables the translational value of the program, ensuring a more comprehensive understanding of SYT-510 effects in patients with generalized anxiety disorders. The plan is to evaluate a single dose of SYT-510 as compared with its matching placebo in a two-way crossover design, separated by a washout period of 7 to 14 days.",[28],"2026-06-16",{"date":59,"type":35},"2026-06-18",{"date":61,"type":35},"2026-04-22",{"date":63,"type":22},"2027-01",{"name":65,"class":42},"Synendos Therapeutics AG",1,{"id":68,"slug":69,"hasResults":12,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":79,"conditions":80,"keywords":84,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100641745","student-precarity-and-psychiatry-100641745","NCT07618208","Student Precarity and Psychiatry","Impact of Precarity on the Emergence of Psychiatric Disorders and the Use of Care Among Students","PEPSY","Inclusion Criteria:\n\n* Student enrolled at Paris Sciences et Lettres University (PSL, 17,000 students) or the Faculty of Health Sciences at Paris Cité University (UPC, 28,000 students),\n* Aged 18 or over,\n* Fluent in French,\n* Affiliated to a health insurance.\n\nExclusion Criteria:\n\n* Applicants under the age of 18,\n* Not enrolled at PSL universities or the UPCS Faculty of Health,\n* Insufficient level of French.",true,{"count":77,"type":22},45000,"OBSERVATIONAL","Since the COVID-19 pandemic, mental health disorders have increased significantly, particularly among young people. In France, the proportion of young people aged 18 to 25 suffering from depression almost doubled between 2017 and 2021. This phenomenon particularly affects students, who are already identified as being at greater risk of mental health disorders than the general population. Medical students seem to be particularly vulnerable: in 2021, a national study showed very high rates of depression and suicidal thoughts in this population. The main factor associated with depression was the feeling of financial hardship.\n\nStudents often face multiple forms of insecurity. Financially, they have limited resources and struggle to cover their basic needs such as housing, food and healthcare. Socially, many experience significant isolation, particularly when they are away from their families or under pressure from their studies. All of this has a significant impact on their mental health. Unfortunately, many students do not seek help due to lack of time, resources, or awareness of support services. The 2021 study showed that only one-third of medical students suffering from depression received appropriate treatment.\n\nThe aim of our study is to assess the impact of precariousness on the onset of psychiatric disorders and on the use or non-use of healthcare services.\n\nOur study will involve nearly 45,000 students from PSL and UPC universities. It is based on a longitudinal cohort (via questionnaires) over three years. The aim is to identify precisely the different aspects of student precariousness (housing, transport, isolation, economic difficulties, etc.) and their link with psychological distress. The study will measure the extent of the phenomenon and identify modifiable factors that could be targeted by preventive measures. The results will enable us to better target preventive measures and propose concrete solutions to improve students' well-being and promote their success.",[81,28,82,83],"Depressive Disorder, Major","Suicidal Ideation","Loneliness",[85,86,87,88],"Students","Depression","Use of care","Precarity","NOT_YET_RECRUITING","2026-06-11",{"date":92,"type":35},"2026-06-15",{"date":94,"type":22},"2026-09",{"date":96,"type":22},"2028-11",{"name":98,"class":99},"Assistance Publique - Hôpitaux de Paris","OTHER",{"id":101,"slug":102,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":23,"phases":110,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":127},"100475189","co2-reactivity-as-a-biomarker-of-non-response-to-exposure-based-therapy-100475189","NCT05467683","CO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy","Carbon Dioxide (CO2) Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy","Inclusion Criteria:\n\n* A primary DSM-5 diagnosis of panic disorder (with or without an agoraphobia diagnosis), social anxiety disorder, generalized anxiety disorder, obsessive-compulsive disorder, or post-traumatic stress disorder as assessed by the Structured Clinical Interview for the DSM-5 (SCID-5)\n* A score of 8 or greater on the Overall Anxiety Severity and Impairment Scale (OASIS)\n* Ages 18 to 70\n* Willingness and ability to provide informed consent and comply with the requirements of the study protocol.\n* Proficiency in English (because assessment instruments have only been validated in English)\n\nExclusion Criteria:\n\n* A lifetime history of bipolar or psychotic disorders, substance use disorders (other than nicotine) or eating disorder in the past 6 months; serious cognitive impairment.\n* Active suicidal ideation with at least some intent to act with or without specific plan (a rating of 4 for suicidal ideation on the Columbia-Suicide Severity Rating Scale) or suicidal behaviors (actual attempt, interrupted attempt, aborted or self-interrupted attempt, or preparatory acts or behavior) within the past 6 months.\n* Medical conditions contraindicating CO2 inhalation or hyperventilation challenge (e.g., cardiac arrhythmia, cardiac failure, asthma, lung fibrosis, high blood pressure, epilepsy, or stroke).\n* Pregnancy or lactation\n* Ongoing psychotherapy directed toward the primary disorder.\n* Pharmacological treatment started within 8 weeks prior to the screen (patients \"stable\" on their medication regimen will be included and their medication status will be included as a variable in the model)","70 Years",{"count":109,"type":22},600,[111],"NA","Anxiety-, obsessive-compulsive and trauma- and stressor-related disorders reflect a significant public health problem. This study is designed to evaluate the predictive power of a novel biomarker based on a CO2 challenge, thus addressing the central question \"can this easy-to-administer assay aid clinicians in deciding whether or not to initiate exposure-based therapy?\"",[114,115,28,116,117],"Obsessive-Compulsive Disorder","Post Traumatic Stress Disorder","Social Anxiety Disorder","Panic Disorder","2026-06-08",{"date":120,"type":35},"2026-06-10",{"date":122,"type":35},"2022-11-02",{"date":124,"type":22},"2027-02-28",{"name":126,"class":99},"Jasper A. Smits",2,{"id":129,"slug":130,"hasResults":12,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":23,"phases":137,"briefSummary":138,"conditions":139,"keywords":141,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":66},"100559375","neurofeedback-enhanced-cognitive-reappraisal-training---phase-4-100559375","NCT06563310","Neurofeedback Enhanced Cognitive Reappraisal Training - Phase 4","Inclusion Criteria:\n\n* Primary diagnosis (primary source of distress and\u002For interference) of generalized anxiety disorder, social anxiety disorder, panic disorder or illness anxiety disorder based on structured interview. Comorbid phobic disorders allowed, but these cannot be the primary source of interference or distress due to the lowered chances of encountering anxiety-provoking stimuli during the study period\n* Score of 2 or more on at least 1 question from GAD\u002FCROSS-AD composite\n* Medically and physically able to consent\n* Not regularly taking any medication, prescription or non-prescription, with psychotropic effects other than:\n\n  1. Buspirone, or antidepressant (e.g., selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI)) with stable dosage for past 4 weeks\n  2. The same oral hormonal contraceptive for at least 3 months\n* For females, not currently pregnant or actively trying to become pregnant\n* Ability to tolerate small, enclosed spaces without anxiety\n* No metals, implants or metallic substances within or on the body that might cause adverse effects to the subject in a strong magnetic field, or interfere with image acquisition (per protocol)\n* Size compatible with scanner gantry (per protocol)\n\nExclusion Criteria:\n\n* Current diagnosis of Obsessive Compulsive Disorder, Posttraumatic Stress Disorder, or Bipolar Disorder\n* Current substance abuse or dependence (past 6 months)\n* Active suicidality with plan or intent\n* Current psychosis\n* History of serious neurological illness or current medical condition that could compromise brain function, such as liver failure\n* History of closed head injury, e.g., loss of consciousness greater (\\>) approximately (\\~) 5 minutes, hospitalization, neurological sequela","24 Years",{"count":136,"type":22},110,[111],"This study seeks to understand emotion regulation in those with young adults with anxiety using real-time functional magnetic resonance imaging neurofeedback, a tool that allows individuals to control brain activity. The goal of this project is to understand how receiving feedback about one's own brain activity relates to emotion regulation ability. This work will help the study team understand the brain areas involved in emotion regulation and could lay the groundwork to test if psychotherapy outcomes can be enhanced using neurofeedback.\n\nThe study hypotheses include:\n\n* Participants receiving veritable-Neurofeedback (NF) will show a greater activation increases in the prefrontal cortex (PFC) compared to sham-NF\n* Participants receiving veritable-NF will show greater cognitive reappraisal (CR) ability compared to those receiving sham-NF\n* PFC activation will positively correlate with CR ability",[140,116,117,28],"Anxiety",[142],"functional magnetic resonance imaging","2026-06-03",{"date":145,"type":35},"2026-06-05",{"date":147,"type":35},"2025-01-09",{"date":149,"type":22},"2029-05",{"name":151,"class":99},"University of Michigan",{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":175},"100500797","triage-survey-for-psychiatry-research-eligibility-100500797","NCT05800925","Triage Survey for Psychiatry Research Eligibility","TRIAGE-Psych","Inclusion Criteria:\n\n* Participant or Legally Authorized Representative has signed an ICF prior to study-specific procedures being performed.\n* Participant is at least 18 years old.\n\nExclusion Criteria:\n\n* Participant is pregnant, breast-feeding, or planning to become pregnant.\n* History of a clinically significant illness which in the investigator's opinion may impact participant safety or the ability to analyze study results.\n* Participant represents an acute suicidal risk, as defined as a \"yes\" response to ideation on C-SSRS questions 4 or 5, or answer \"yes\" to behavior questions within 90 days of screening.\n* Moderate or severe substance use disorder within 90 days prior to screen, according to DSM-5 criteria that in the investigator's opinion could pose undue risk to the participant.\n* Any condition that in the investigator's opinion makes a participant unsuitable for the study.\n* Currently employed by Adams Clinical or a first-degree relative of an employee.",{"count":160,"type":22},20000,"TRIAGE-Psych is a survey study designed to assess potential participants' eligibility to screen for industry-sponsored psychiatry clinical trials.",[163,164,28],"Major Depressive Disorder","Borderline Personality Disorder","2026-05-18",{"date":167,"type":35},"2026-05-20",{"date":169,"type":35},"2021-12-21",{"date":171,"type":22},"2027-12-31",{"name":173,"class":174},"Adams Clinical","NETWORK",6,{"id":177,"slug":178,"hasResults":12,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":12,"sex":17,"minAge":184,"maxAge":18,"enrollmentInfo":185,"targetDuration":4,"studyType":23,"phases":187,"briefSummary":188,"conditions":189,"keywords":201,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":66},"100587910","implementing-team-based-treatment-for-pediatric-anxiety-in-community-mental-health-settings-100587910","NCT06934525","Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings","Testing Delivery of Modalities in Community Health Settings: Developing Pathways to Health Equity","IMPACT-RI","Inclusion Criteria:\n\n* Age 5-18 inclusive\n* Primary or co-primary DSM-V diagnosis of anxiety or OCD\n* Symptom duration of at least 3 months\n* Outpatient care needed\n* Presence of a stable parent, or guardian, who can participate in treatment\n\nExclusion Criteria:\n\n* Other primary or co-primary psychiatric disorder which requires initiation of other active current treatment\n* Acute suicidality\n* Concurrent psychotherapy\n* Chronic medical illness that would preclude their active participation in treatment\n* Treatment with psychotropic medication that is not stable","5 Years",{"count":186,"type":22},501,[111],"The purpose of this study is to test how the delivery of Cognitive Behavioral Therapy (CBT) for pediatric anxiety and OCD via different methods might increase its availability and effectiveness. CBT involves teaching the patient skills to enable them to gradually come into contact with feared situations. This process of gradually approaching feared situations is called exposure. Although CBT with exposure has the best evidence for treating anxiety disorders, not all children have equal access or respond the same way to CBT. As part of this study, patients will receive weekly CBT treatment sessions involving a combination of weekly visits with an exposure coach and one visit a month with a licensed provider (e.g., psychologist, social worker). This treatment will be delivered using one of three methods: 1) in-person (face-to-face sessions, occurring in the office and the home\u002Fcommunity), or 2) telehealth (entirely remote sessions via web-based video conference), or 3) flexible (individualized mix of in-person and\u002For telehealth sessions). Eligible participants will be randomly assigned to one of these three methods. Results of this study will help determine which treatment method works best for whom.\n\nTreatment as described above will occur as part of care at partnering community care sites in Rhode Island. Providers from the following partnering community care sites will make up patient treatment teams: Blackstone Valley Community Health Care, Family Services of Rhode Island, Gateway Healthcare, Newport Mental Health, and Thrive Behavioral Health.\n\nThe research study is being conducted by the Pediatric Anxiety Research Center at Brown University Health. The research team will conduct the study assessments that patients will be asked to participate in as study participants. Patients will be asked to complete assessments prior to starting treatment, at two time points during treatment, at the end of treatment, and at two timepoints 3 and 6 months following the end of treatment. Participants will be compensated for their time completing research assessments.",[190,191,192,140,193,194,195,196,28,197,198,199,116,117,200],"Obsessive Compulsive Disorder (OCD)","Pediatric Anxiety Disorders","Anxiety Disorder","OCD","Phobia","Agoraphobia","Generalized Anxiety","Selective Mutism","Separation Anxiety","Social Anxiety","Pediatric Disorders",[202,203,204,205,206,207],"exposure therapy","cognitive behavioral therapy","anxiety treatment","exposure and response prevention therapy","ERP","pediatric anxiety treatment","2026-05-13",{"date":210,"type":35},"2026-05-14",{"date":212,"type":35},"2025-11-01",{"date":214,"type":22},"2029-08-01",{"name":216,"class":99},"Bradley Hospital",{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":23,"phases":225,"briefSummary":226,"conditions":227,"keywords":228,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":127},"100640968","group-vs-individual-metacognitive-therapy-for-generalized-anxiety-disorder-100640968","NCT07579897","Group vs. Individual Metacognitive Therapy for Generalized Anxiety Disorder","Generalized Anxiety Disorder: A Randomized Non-inferiority Trial Comparing Group Metacognitive Therapy With Individual Metacognitive Therapy","Inclusion Criteria:\n\nAdults with a primary diagnosis of generalized anxiety disorder (GAD). GAD-7 score ≥ 10 at screening\u002Fbaseline. Participants must endorse that they experience problems with excessive worry\n\nExclusion Criteria:\n\n1. Bipolar disorder;\n2. Psychosis;\n3. Ongoing substance abuse\u002Fdependence;\n4. Intellectual disability based on previous medical history;\n5. Eating disorder in need of medical attention;\n6. Unwillingness to refrain from anxiolytic drugs during the treatment;\n7. Current suicidal ideation with plan and intent;\n8. Taking an unstable dose of antidepressant, with recent dose-change within the last 4 weeks;\n9. Known cluster A or B personality disorder;\n10. Serious medical comorbidity (e.g.: cancer, severe renal failure)\n11. Language difficulties in need of an interpreter.",{"count":21,"type":22},[111],"Generalized anxiety disorder (GAD) is a serious and long-lasting condition that can greatly reduce quality of life, work functioning, and use of health services. Metacognitive therapy (MCT) is an effective treatment for GAD, but it is not yet known whether individual MCT or group-based MCT provides the best results for patients.\n\nThis randomized controlled trial will compare two formats of MCT: individual treatment and group-based treatment (g-MCT). A total of 64 adults with GAD (32 in each treatment arm) will participate after providing informed consent. Participants will complete questionnaires, undergo clinical assessments, and allow the study to collect relevant health information from official registries.\n\nThe main aim of the study is to determine whether group-based MCT is non-inferior to individual MCT. A non-inferiority design tests whether the group format is not meaningfully less effective than the individual format. If group MCT is shown to have similar effects on anxiety symptoms and functioning, it could offer an efficient and resource-saving alternative in routine clinical care.\n\nThis will be the first study to systematically compare these two treatment formats in a real-world clinical setting. If group MCT proves to be as effective as individual therapy, it may help increase access to evidence-based treatment for people with GAD, reduce strain on mental health services, and support the development of more accessible and cost-effective care.",[28],[28,30,140,229,230,231,232,233,234,235,236,237,238,239,240,241],"Metacognitive Therapy","MCT","Group Metacognitive Therapy","Individual Metacognitive Therapy","Worry","Psychotherapy","RCT","Randomized Controlled Trial","Anxiety Treatment","Group Therapy","Adult Mental Health","Cognitive Attentional Syndrome","CAS","2026-05-06",{"date":244,"type":35},"2026-05-12",{"date":246,"type":35},"2026-03-27",{"date":248,"type":22},"2028-12",{"name":250,"class":251},"Sorlandet Hospital HF","OTHER_GOV",{"id":253,"slug":254,"hasResults":12,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":259,"enrollmentInfo":260,"targetDuration":4,"studyType":23,"phases":262,"briefSummary":263,"conditions":264,"keywords":267,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":283,"locationsCount":66},"100423436","a-transdiagnostic-self-guided-internet-intervention-velibra-for-waitlist-patients-with-anxiety-disorders-100423436","NCT04793828","A Transdiagnostic, Self-guided Internet Intervention (\"Velibra\") for Waitlist Patients With Anxiety Disorders","The Effect of a Transdiagnostic, Self-guided Internet Intervention (\"Velibra\") for Waitlist Patients With Anxiety Disorders","Inclusion Criteria:\n\n* Diagnosis of panic disorder with or without agoraphobia, social anxiety disorder, or generalized anxiety disorder\n* Knowledge of German that is sufficient for engaging with the treatment and responding to the questionnaires\n* Written informed consent\n* Internet access\n\nExclusion Criteria:\n\n* Diagnoses of severe mental comorbidities (e.g., schizophrenia, severe major depression, borderline personality disorder)\n* Acute suicidality\n* Started or changed anxiolytic pharmacotherapy recently (currently or in the past four weeks)","65 Years",{"count":261,"type":22},30,[111],"The project's aim is to investigate the effect of a transdiagnostic, self-guided, internet-based cognitive behavioral therapy program in waitlist patients with anxiety disorders.",[265,266,28,116],"Panic Disorder With Agoraphobia","Panic Disorder Without Agoraphobia",[203,268,269,270,271,272,273,274,275,276,277],"internet intervention","administrative-supported","anxiety","panic disorder","social anxiety disorder","generalized anxiety disorder","computerized CBT","anxiety disorders","velibra","psychotherapy",{"date":279,"type":35},"2026-05-07",{"date":281,"type":35},"2020-07-04",{"date":171,"type":22},{"name":284,"class":99},"Charite University, Berlin, Germany",{"id":286,"slug":287,"hasResults":12,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":291,"eligibilityCriteria":292,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":293,"enrollmentInfo":294,"targetDuration":4,"studyType":23,"phases":295,"briefSummary":296,"conditions":297,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":4},"100639864","the-effect-of-yoga-assisted-cognitive-behavioral-therapy-on-individuals-diagnosed-with-generalized-anxiety-disorder-100639864","NCT07577271","THE EFFECT OF YOGA-ASSISTED COGNITIVE BEHAVIORAL THERAPY ON INDIVIDUALS DIAGNOSED WITH GENERALIZED ANXIETY DISORDER","THE EFFECT OF A YOGA-ASSISTED COGNITIVE BEHAVIORAL THERAPY-BASED ANXIETY REDUCTION PROGRAM ON PSYCHOLOGICAL RESILIENCE, FUNCTIONING, AND ANXIETY LEVELS IN INDIVIDUALS DIAGNOSED WITH GENERALIZED ANXIETY DISORDER","YOGA-CBT","Inclusion Criteria:\n\n* VOLUNTEER TO PARTICIPATE IN THE STUDY AND HAVE GIVEN WRITTEN CONSENT\n* ACCORDING TO ICD-10 CRITERIA, HAVING BEEN DIAGNOSED WITH GENERALIZED ANXIETY DISORDER (GAD) FOR THE LAST 1 YEAR.\n* BEING BETWEEN 18 AND 60 YEARS OLD\n* KNOWING HOW TO READ AND WRITE IN TURKISH\n* LACK OF ANY ACTIVE PSYCHOTHERAPY PROCESS AND NOT ACTIVELY PRACTICING YOGA\n\nExclusion Criteria:\n\n* HAVING ANY ORGANIC DISEASE OR PSYCHOTIC ILLNESS\n* HAVING ANY SENSORY OR COGNITIVE IMPAIRMENT\n* THE PRESENCE OF ANY COMORBID PSYCHIATRIC DISORDER","60 Years",{"count":21,"type":22},[111],"THIS STUDY EXAMINED 64 INDIVIDUALS WHO WERE DIAGNOSED WITH GENERALIZED ANXIETY DISORDER ACCORDING TO ICD-10 DIAGNOSTIC CRITERIA AND RECEIVED OUTPATIENT TREATMENT AT THE PSYCHIATRY POLYCLINIC OF İSKENDERUN STATE HOSPITAL BETWEEN SEPTEMBER 1, 2025, AND JULY 24, 2026, AND WHO MET THE INCLUSION AND EXCLUSION CRITERIA.",[28],"2026-05-05",{"date":300,"type":35},"2026-05-11",{"date":302,"type":22},"2026-05-15",{"date":304,"type":22},"2026-09-20",{"name":306,"class":99},"Merve Sevim TEKİN",{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":259,"enrollmentInfo":314,"targetDuration":4,"studyType":23,"phases":316,"briefSummary":317,"conditions":318,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":66},"100595112","mindful-self-compassion-for-anxiety-and-depression-impact-of-delivery-method-100595112","NCT07028216","Mindful Self-compassion for Anxiety and Depression: Impact of Delivery Method","Mindful Self-Compassion for Anxiety and Depression: A Randomized Comparison of In-Person Versus Videoconference Delivery","Inclusion Criteria:\n\n* Must have a primary anxiety disorder (social anxiety disorder, generalized anxiety disorder, panic disorder, or agoraphobia) or major depressive disorder, current\n* Must score low on self-compassion, as measured by the self-compassion scale\n* Must understand study procedure and willing to participate in all testing visits, and treatment as assigned\n* Must be able to give informed consent to the study procedures\n\nExclusion Criteria:\n\n* Comorbid psychiatric disorder other than anxiety or depression, such as psychotic disorder, obsessive compulsive disorder, eating disorders (i.e., anorexia and bulimia), bipolar disorder; developmental or organic mental disorders; and current (past 6 months) substance use disorders and current post-traumatic stress disorder as assessed by clinician at screening visit\n* A serious medical condition that may result in surgery or hospitalization.\n* A history of head trauma causing prolonged loss of consciousness, or ongoing cognitive impairment\n* Inability to understand study procedures or informed consent process, or significant personality dysfunction likely to interfere with study participation (assessed during the clinical interview).\n* Subjects who will be non-compliant with the study procedures. This may include planned travel out of town.\n* Subjects taking some psychiatric medication such as barbiturates or antipsychotics. Sleep medications and some anti-depressants will be allowed, if the subject has been taken at stable dose 8 weeks prior to baseline and the patient plans to continue at the same dose through the trial.\n* Concurrent psychotherapy initiated within 1 month of screen interview, or ongoing psychotherapy of any duration directed specifically toward the treatment of anxiety (such as Cognitive Behavioral Therapy).\n* Individuals who have completed a course of MSC or an equivalent meditation training in the last year.\n* Individuals reporting significant active suicidal ideation or suicidal behaviors within the past year.\n* Individuals with a medical condition (i.e., epilepsy) that may be exacerbated by study treatment, as determined by a study physician or nurse practitioner based on history, physical, and\u002For labs.\n* Adults unable to consent\n* Pregnant women\n* Prisoners",{"count":315,"type":22},80,[111],"The study will compare the delivery of an 8-week Mindful Self-Compassion training, in-person against video-conference, on anxiety and depression symptom severity in patients with diagnosed anxiety disorders (generalized anxiety disorder, social anxiety disorder, and panic disorder) or major depressive disorder or dysthymia.",[319,28,116,117,195,163,320],"Anxiety Disorders","Persistent Depressive Disorder (Dysthymia)","2026-05-03",{"date":298,"type":35},{"date":324,"type":35},"2025-06-01",{"date":326,"type":22},"2027-08-31",{"name":328,"class":99},"Georgetown University",{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":75,"sex":17,"minAge":18,"maxAge":107,"enrollmentInfo":336,"targetDuration":4,"studyType":23,"phases":337,"briefSummary":339,"conditions":340,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":66},"100628096","phase-1-pharmacokinetic-study-of-buagafuran-capsules-in-participants-with-hepatic-impairment-and-normal-hepatic-function-100628096","NCT07457190","Pharmacokinetic Study of Buagafuran Capsules in Participants With Hepatic Impairment and Normal Hepatic Function","Pharmacokinetic and Safety Study of Buagafuran Capsules in Participants With Hepatic Impairment and Normal Hepatic Function","Inclusion Criteria:\n\n1. Voluntarily sign an informed consent form before the start of activities related to this trial, understand the procedures and methods of this trial, and be willing to strictly follow the clinical trial protocol to complete this trial;\n2. Participants (including partners) are willing to have no fertility plans from screening to within 6 months after the last administration of the study drug, and voluntarily adopt highly effective contraceptive measures;\n3. On the day of signing the informed consent form, the age range is 18 to 70 years old (including both ends), and both males and females are eligible;\n4. Male participants should weigh no less than 50 kg, and female participants should weigh no less than 45 kg; Body Mass Index (BMI) should be between 18 and 32 kg\u002Fm2 (including both ends), with BMI=weight (kg)\u002Fheight (m2);\n5. Creatinine clearance rate ≥ 60 mL\u002Fmin;\n6. Participants with normal hepatic function must also meet all of the following criteria: a): Weight matching with the hepatic impairment group, with an average weight range of ± 10 kg; b): Age matching with the hepatic impairment group, with an average age range of ± 10 years; c): The number of participants of each gender is similar to that of the hepatic impairment group (mean ± 1 participant\u002Fgender);\n7. Participants with hepatic impairment must also meet all of the following conditions: a): Chronic hepatic impairment caused by primary hepatic diseases, and hepatic impairment patients with Child Pugh classification of A or B; b):The clinical diagnosis is cirrhosis; c): Individuals who have a stable medication regimen for treating hepatic impairment, complications, and other accompanying diseases for at least 14 days prior to taking the investigational drug, and whose medication does not require adjustment; or those who have not taken medication;\n\nExclusion Criteria:\n\n1. Allergic constitution, including individuals with a history of severe drug allergies or drug hypersensitivity reactions, known to be allergic to the study drug or any component of the study drug;\n2. During the screening period, the electrocardiogram showed a QTc interval of\\>470 milliseconds in males and\\>480 milliseconds in females;\n3. Individuals with a history of swallowing difficulties or any gastrointestinal diseases that affect drug absorption, including frequent nausea or vomiting caused by any underlying cause;\n4. Those who need treatment for bacterial, viral, parasitic or fungal infection with any clinical symptoms during screening (excluding hepatitis B and hepatitis C), and those who have a history of serious active infection within 1 month before screening;\n5. Individuals who have undergone major surgeries within the previous 6 months (defined as surgeries involving intracranial, chest, abdominal, pelvic, or limb organs that cause significant tissue trauma and require long-term recovery (such as organ transplantation, heart surgery, or joint replacement), or those who plan to undergo surgery during the study period; Individuals with a history of liver transplantation; Participants who have undergone surgery that may affect drug absorption, distribution, metabolism, and excretion in the past (such as gastric and duodenal resection surgery) or who may be hospitalized due to surgery or other reasons during the expected trial period;\n6. Screening individuals who have received the vaccine within the previous 14 days or plan to receive the vaccine during the study period;\n7. Screening individuals who have donated blood or lost blood ≥ 200 mL within the first 3 months, or plan to donate blood during the trial period or within 1 month after the trial ends;\n8. Screening for individuals who have used other clinical trial drugs within the previous 3 months or plan to participate in other clinical trials during the study period;\n9. Within one month prior to screening (or 5 times the half-life, whichever is longer), strong or moderate inducers or inhibitors of CYP2B6, CYP3A4, renal transporter inhibitors, etc. have been used;\n10. Consuming grapefruit or products containing grapefruit, food or beverages containing caffeine, xanthine, or alcohol (including chocolate, tea, coffee, cola, etc) 48 hours prior to receiving the investigational drug; Those who engage in vigorous exercise or have other factors that affect drug absorption, distribution, metabolism, excretion, etc;\n11. Screening for alcoholics within the first 3 months, those who consume more than 14 units of alcohol per week (1 unit=360 mL of beer, 45 mL of strong liquor with an alcohol content of 40%, or 150 mL of wine) or have a positive alcohol screening result; Individuals who smoke an average of 10 or more cigarettes per day within the first 3 months of screening;\n12. Individuals with a history of drug use, drug abuse, or positive drug abuse screening;\n13. Pregnant or lactating women, or women of childbearing age who test positive for pregnancy;\n14. Those who cannot tolerate venipuncture or have a history of needle and blood dizziness;\n15. Other reasons why researchers believe it is not suitable for inclusion;\n\n    Participants with normal hepatic function who meet any of the following exclusion criteria need to be excluded:\n16. History of hepatic impairment;\n17. Individuals who have previously or currently suffered from any clinically serious diseases such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematology, immunology, psychiatry, and metabolic abnormalities, or any other diseases that may interfere with the test results;\n18. Abnormal physical examination, vital signs, laboratory tests, 12 lead electrocardiogram, abdominal ultrasound and other examinations have clinical significance as determined by the researchers;\n19. Those who are positive in any index screening of hepatitis B surface antigen, hepatitis C antibody, HIV antigen\u002Fantibody or syphilis antibody;\n20. Have used any prescription drugs, over-the-counter drugs, herbal medicines, or supplements within 14 days prior to receiving the investigational drug.\n\n    Participants with hepatic impairment who meet any of the following exclusion criteria must be excluded:\n21. Participants have any of the following conditions: acute hepatic function damage caused by various reasons; History of liver transplantation; And researchers believe that patients with liver cirrhosis complicated with the following complications: including but not limited to hepatic failure, hepatic encephalopathy, hepatocellular carcinoma (excluding liver cancer patients who have received curative treatment and have not relapsed; excluding liver cancer patients with BCLC stage 0), and those who have experienced esophageal and gastric variceal bleeding within the past 3 months before screening;\n22. The laboratory test results during screening meet any of the following criteria: (a) ALT or AST\\>10 × ULN; (b) NE#\\\u003C0.75×109\u002FL；(c) HGB\\\u003C60 g\u002FL； (d) AFP\\>100 ng\u002FmL; (e) Platelet count\\\u003C40 × 109\u002FL; any remaining abnormalities that have clinical significance and have been determined by the researchers to be unsuitable for participation in this trial;\n23. Individuals who test positive for HIV antigen\u002Fantibody screening; If syphilis antibodies are positive, rapid plasma reagin (RPR) testing should be added. If RPR is also positive, it should be excluded;\n24. In addition to the primary liver disease itself, those who have previously or currently suffered from other serious organ systemic diseases, including but not limited to gastrointestinal, respiratory, renal, neurological, blood, endocrine, tumor, immune, psychiatric or cardiovascular diseases, or abnormalities with clinical significance such as physical examination and chest radiograph, and have been determined by the research doctor to be unsuitable for participation in this trial.",{"count":53,"type":22},[338],"PHASE1","This study adopts a non-randomized, open label, parallel, single-dose design to evaluate the safety and pharmacokinetic characteristics of Buagafuran capsules in participants with hepatic impairment.",[28],"2026-03-08",{"date":343,"type":35},"2026-03-10",{"date":345,"type":22},"2026-03",{"date":347,"type":22},"2026-12",{"name":349,"class":42},"Beijing Union Pharmaceutical Factory Ltd",{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":12,"sex":17,"minAge":357,"maxAge":358,"enrollmentInfo":359,"targetDuration":4,"studyType":23,"phases":361,"briefSummary":362,"conditions":363,"keywords":366,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":66},"100588517","stepped-versus-stratified-care-for-anxiety-disorders-in-youth-100588517","NCT06942429","Stepped Versus Stratified Care for Anxiety Disorders in Youth","Stepped Versus Stratified Care for Anxiety Disorders in Youth: A Pragmatic Non-Inferiority Randomized Controlled Trial","Inclusion Criteria:\n\n1. Aged 8.0 to 17.5 years. Confirmed by the child and\u002For caregiver.\n2. Principal DSM-5-TR anxiety disorder of social anxiety disorder, generalized anxiety disorder, panic disorder, separation anxiety disorder, specific phobia, or agoraphobia. Confirmed by the structured diagnostic interview (DIAMOND-KID). \"Principal\" indicates that the anxiety disorder is judged by the clinician to be in most urgent need of treatment (among potential co-occurring disorders).\n3. Available caregiver who can support the child in treatment. Confirmed by the caregiver.\n4. Child and at least one caregiver can read, write, and communicate in Swedish. Confirmed by the child and\u002For caregiver.\n5. Child (≥13 years) and caregiver have access to a Swedish electronic identification (BankID or Freja eID).\n6. Access to the internet. Confirmed by the child and\u002For caregiver.\n7. Ability to attend in-person CBT sessions at the clinic. Confirmed by the child and\u002For caregiver.\n\nExclusion Criteria:\n\n1. Principal DSM-5-TR anxiety disorder of specific phobia concerning the domain of blood-injection-injury (due to the ICBT program not including relevant information on applied-tension techniques to avoid fainting during exposure exercises). Confirmed by a specific phobia of this sort being classified as the most functionally impairing anxiety disorder during the structured diagnostic interview (DIAMOND-KID).\n2. Ongoing psychological treatment for an anxiety disorder. Confirmed by the child and\u002For caregiver.\n3. Social\u002Ffamilial\u002Feducational difficulties in more immediate need of management than an anxiety disorder. Confirmed by the assessor through information from the child and\u002For caregiver and\u002For other available sources.\n4. Immediate risk to self or others that require urgent attention, such as suicidality. Confirmed by the assessor through information from the child and\u002For caregiver and other available sources.\n5. The potential participant has a relative (e.g., sibling, cousin) included in the study. Confirmed by the assessor through information from the caregiver and other available sources.","8 Years","17 Years",{"count":360,"type":22},556,[111],"The goal of this clinical trial is to compare stepped care to stratified care as overall healthcare models for children and adolescents aged 8-17 with anxiety disorders. It addresses one main question:\n\n• Is stepped care non-inferior to stratified care in supporting participants to achieve a treatment response?\n\nResearchers will compare two care models:\n\n* Stepped care, where all participants begin with 14 weeks of internet-delivered cognitive behavioral therapy (ICBT) and receive an additional 14 weeks of personalized in-person CBT if needed.\n* Stratified care, where participants are assigned to either 14 weeks of ICBT or 14 weeks of in-person CBT based on clinical complexity, and may also receive additional 14 weeks of in-person CBT if necessary.\n\nParticipants will:\n\n* Be randomly assigned to one of the two care models.\n* Complete a wide range of assessments at baseline, during treatment, and at 4, 8, 12, and 24 months, with the 8-month point as the primary endpoint.\n* Receive either ICBT, in-person CBT, or both, depending on their care model and response to treatment.\n* Participate in ancillary studies involving DNA sampling, cognitive testing, and national registry linkages to help predict treatment response and long-term outcomes.",[116,364,365,117,28,195],"Separation Anxiety Disorder","Specific Phobia",[275,367,368,203,369,370,371,372],"children","adolescents","non-inferiority","care models","stepped care","stratified care","2026-02-24",{"date":375,"type":35},"2026-02-27",{"date":377,"type":35},"2025-06-19",{"date":379,"type":22},"2031-03-05",{"name":381,"class":99},"Region Skane",{"id":383,"slug":384,"hasResults":12,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":4,"eligibilityCriteria":388,"healthyVolunteers":12,"sex":17,"minAge":357,"maxAge":358,"enrollmentInfo":389,"targetDuration":4,"studyType":23,"phases":391,"briefSummary":392,"conditions":393,"keywords":395,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":66},"100566921","internet-delivered-cognitive-behavioral-intervention-for-youths-with-anxiety-disorders-100566921","NCT06661460","Internet-Delivered Cognitive Behavioral Intervention for Youths With Anxiety Disorders","Development and Preliminary Evaluation of a New Internet-Delivered Cognitive Behavioral Intervention for Youths With Anxiety Disorders","Inclusion Criteria:\n\n1\\) 8 to \\\u003C18 years of age.\n\n* Confirmed by the child\u002Fcaregiver and subsequently by the medical record system. 2) A principal DSM-5-TR anxiety disorder of specific phobia, separation anxiety disorder, social anxiety disorder, generalized anxiety disorder, panic disorder or agoraphobia.\n* Confirmed by the Diagnostic Interview for Anxiety, Mood, and OCD and related Neuropsychiatric Disorders - Child and Adolescent Version (DIAMOND-KID).\n\n  3\\) Child and caregiver able to read, write and communicate in Swedish.\n* Confirmed by the child\u002Fcaregiver. 4) An available caregiver who can support the child in treatment.\n* Confirmed by the caregiver. 5) Access to a smartphone, tablet, or laptop\u002Fdesktop device, and the internet.\n* Confirmed by the child\u002Fcaregiver.\n\nExclusion Criteria:\n\n1\\) Principal DSM-5-TR anxiety disorder of specific phobia concerning the domain of blood-injection-injury (due to the ICBT program not including relevant information on applied-tension techniques to avoid fainting during exposure exercises).\n\n* Confirmed by a blood-injection-injury phobia being classified as the principal anxiety disorder as assessed by the DIAMOND-KID.\n\n  2\\) Established or suspected intellectual disability.\n* Confirmed by the caregiver (through previous diagnosis) and\u002For by attending a special needs school for learning difficulties.\n\n  3\\) Another mental disorder in more immediate need of management than an anxiety disorder (e.g., schizophrenia spectrum and other psychotic disorders, bipolar disorder, anorexia nervosa, substance use disorders).\n* According to the DIAMOND-KID and\u002For other available sources. 4) Social\u002Ffamilial\u002Feducational difficulties in more immediate need of management than an anxiety disorder.\n* Confirmed by the assessor through information from the child\u002Fcaregiver and\u002For other available sources.\n\n  5\\) Immediate risk to self or others that require urgent attention, such as acute suicidality.\n* Confirmed by the assessor through information from the child\u002Fcaregiver and other available sources.\n\n  6\\) Previous CBT for an anxiety disorder, defined as five or more sessions with a certified CBT therapist within the 12 months prior to assessment.\n* Confirmed by the child\u002Fcaregiver or the medical record system. 7) Ongoing psychological treatment for an anxiety disorder.\n* Confirmed by the child\u002Fcaregiver or the medical record system. 8) Initiation or adjustment of any psychotropic medication for anxiety (i.e., selective serotonin reuptake inhibitors, tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitor or antipsychotics) within 8 weeks prior to assessment.\n* Confirmed by the child\u002Fcaregiver or the medical record system. 9) Participation in user involvement sessions in the present study.\n* Confirmed by the researcher.",{"count":390,"type":22},48,[111],"The goal of this study is to develop a new internet-delivered cognitive behavioral therapy (ICBT) intervention for youths with anxiety disorders based on the best current knowledge about effective cognitive behavioral therapy for the target group, refine the intervention in collaboration with patient and public representatives, and conduct a preliminary evaluation of the treatment effects in an open clinical trial.\n\nThe primary objective of the study is:\n\n1\\. To evaluate the preliminary efficacy of a newly developed ICBT intervention for children and adolescents with anxiety disorders in reducing anxiety severity, as measured by the Pediatric Anxiety Rating Scale (PARS).\n\nSecondary objectives of the study are:\n\n1. To examine the preliminary efficacy (PARS) of the ICBT intervention at 3 months post-treatment.\n2. To examine how youths with anxiety disorders, their caregivers, therapists, and healthcare leadership experience the ICBT intervention.\n3. To examine factors (e.g., age, type of anxiety disorder, presence of depressive symptoms, experiences of ICBT) that predict treatment outcome.\n4. To examine how the ICBT intervention can be improved (e.g., treatment content and technical delivery) for future use.\n\nParticipants will:\n\n* Undergo ICBT treatment for anxiety disorders during 12 weeks\n* Complete questionnaires at multiple time points throughout the study\n* Participate in follow-ups post-treatment and 3 months post-treatment\n* A selection of participants will also be invited to focus group interviews with the aim to generate ideas on how the intervention may be improved for future use",[394,365,116,364,28,117,195],"ANXIETY DISORDERS (or Anxiety and Phobic Neuroses)",[396,397,398,399,400,401,402],"Anxiety disorders","Children","Adolescents","Cognitive Behavioral Therapy","Remote delivery","Internet","Internet-delivered cognitive behavioral therapy","2026-02-19",{"date":405,"type":35},"2026-02-20",{"date":407,"type":35},"2025-12-12",{"date":409,"type":22},"2027-06-01",{"name":411,"class":99},"Lund University",{"id":413,"slug":414,"hasResults":12,"nctId":415,"briefTitle":416,"officialTitle":417,"acronym":418,"eligibilityCriteria":419,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":259,"enrollmentInfo":420,"targetDuration":4,"studyType":23,"phases":422,"briefSummary":423,"conditions":424,"keywords":430,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":127},"100545041","phase-2-search-for-novel-transcranial-magnetic-stimulation-tms-targets-for-mental-illness-100545041","NCT06376734","Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness","Transdiagnostic Circuit Mapping of Prefrontal Targets in Accelerated Transcranial Magnetic Stimulation","Expedition","Inclusion Criteria:\n\n* Age 18-65\n* English proficiency sufficient for informed consent, questionnaires\u002Ftasks, and treatment\n* Primary diagnosis of one of the following: major depressive disorder (MDD), obsessive-compulsive disorder (OCD), generalized anxiety disorder (GAD), or schizophrenia (determined by focal assessment using the Structured Clinical Interview for DSM-5)\n\n  * ≥20 on the Beck Depression Inventory for patients with MDD\n  * ≥16 on the Beck Anxiety Inventory for patients with GAD\n  * ≥16 on the Yale-Brown Obsessive-Compulsive Scale for patients with OCD\n  * ≥58 on the Positive and Negative Symptom Scale for patients with schizophrenia\n* Stable psychotropic medication regimen, or remain medication free, for 4 weeks prior to treatment (Medication changes during study enrollment period will be tracked for post hoc analysis).\n* Primary clinician (e.g. psychiatrist, therapist, psychologist, APRN, PA, etc.) responsible for psychiatric care before, during, and after the trial\n\nExclusion Criteria:\n\n* Active pregnancy as determined by a urine pregnancy test\n* Cluster B personality disorders (antisocial personality disorder, borderline personality disorder, histrionic personality disorder, narcissistic personality disorder)\n* PTSD with active, clinically significant symptoms, as determined by clinician\n* Diagnosis of Schizoaffective Disorder, Bipolar Type\n* Recent (within 4 weeks) or concurrent use of rapid-acting antidepressant agent (ketamine\u002Fesketamine\u002FECT)\n* Ferromagnetic metallic implant that would contraindicate receiving TMS or obtaining MRI\n* Any other TMS or MRI safety concerns identified by the clinician\n* Receiving or planning to receive other TMS treatments during course of participation\n* History of:\n\n  * Neurosurgical intervention for mental illness\n  * Moderate to severe autism spectrum disorder\n  * Intellectual disability\n  * Severe cognitive impairment\n  * Significant neurological illness (e.g., dementia, Parkinson's, Huntington's, brain tumor, seizure disorder, subdural hematoma, multiple sclerosis)\n  * Untreated or insufficiently treated endocrine disorder\n  * Eating disorders\n  * Treatment with investigational drug or intervention during the study period\n* Current evidence of:\n\n  * Mania or hypomania\n  * Active suicidal ideation or a suicide attempt within the past year\n  * Contraindications to either TMS or MRI (e.g., metallic implants, etc.).\n  * Current moderate or severe substance use disorder or demonstrating signs of acute substance withdrawal\n  * Significantly increased seizure risk as determined by a clinician\n* For participants with schizophrenia:\n\n  * Evidence of impaired capacity to consent, e.g. impaired insight into illness, as deemed by a licensed psychiatrist or psychologist on the study team\n  * Hospitalization with psychosis in the past 6 months\n* Positive urine drug screen for illicit substances\n* Existing tinnitus (ringing in the ears)\n* Any other condition deemed by the PI to interfere with the study or increase risk to the participant",{"count":421,"type":22},180,[25],"Participants will receive Transcranial Magnetic Stimulation (TMS) at a random location in the left prefrontal cortex, excluding sites that are potentially unsafe. Extensive behavioral testing will be conducted to determine which behaviors are modulated by stimulating which circuits.",[163,114,425,28,426,427,428,429],"Schizophrenia","Mood Disorders","Psychiatric Disorder","Mental Disorder","Depression, Anxiety",[431,270,432,193,433,434,435,436,437,438,439,440,441,442,443,444],"depression","schizophrenia","obsessive-compulsive disorder","transcranial magnetic stimulation","TMS","accelerated TMS","accelerated intermittent theta burst stimulation","brain stimulation","neuromodulation","transdiagnostic","neuronavigation","functional connectivity","neuroimaging","theta burst stimulation","2026-02-13",{"date":447,"type":35},"2026-02-17",{"date":449,"type":35},"2025-01-30",{"date":451,"type":22},"2030-06-01",{"name":453,"class":99},"Brigham and Women's Hospital",{"id":455,"slug":456,"hasResults":12,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":4,"eligibilityCriteria":460,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":259,"enrollmentInfo":461,"targetDuration":4,"studyType":23,"phases":462,"briefSummary":463,"conditions":464,"keywords":465,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":474,"locationsCount":476},"100405324","low-intensity-focused-ultrasound-pulsation-lifup-for-the-treatment-of-generalized-anxiety-disorder-gad-100405324","NCT04557891","Low-Intensity Focused Ultrasound Pulsation (LIFUP) for the Treatment of Generalized Anxiety Disorder (GAD)","Feasibility of Low-Intensity Focused Ultrasound Pulsation (LIFUP) for the Treatment of Generalized Anxiety Disorder (GAD)","Inclusion Criteria:\n\n1. Male or female\n2. Age 18-65\n3. Normal or corrected-to normal vision and hearing\n4. Primary diagnosis of generalized anxiety disorder, moderate\u002Fsevere per DSM-5. (HAM-A\\>17) 4a) The duration of the illness must exceed one year.\n5. Must be medically stable as determined by investigator\n6. Patient must have attempted and failed treatment with at least 2 SSRI and 1 augmentation\n7. History of rTMS is permitted, but not required.\n\nExclusion Criteria:\n\n1. Diagnosis of primary DSM-5 anxiety disorder other than GAD 1a) Affective disorders such as unipolar or bipolar depression are permitted as long as GAD is primary\n2. Current use of any non-prescribed psychoactive medications or drugs (aside from medications for treatment of GAD)\n3. Contraindication to enter the MRI environment\n4. Pregnancy (or suspected\u002Fpossible pregnancy or plan to become pregnant in the short-term)\n5. Inability to adhere to treatment schedule\n6. Initiation of new anxiolytic treatment at the time of study randomization",{"count":390,"type":22},[111],"There are few treatment options available for patients once they have failed standard psychopharmacological therapy for generalized anxiety disorder. Existing brain stimulation methods such as rTMS fail to target deep brain structures associated with anxiety disorders; structures such as the amygdala. In this double-blind sham-controlled clinical trial, the investigators propose to establish baseline severity of anxiety in 48 patients, then deliver eight treatments over four sessions of focused ultrasound stimulation to the amygdala. Anxiety severity will be assessed using standard psychometric scales after each session, and at follow-ups.",[28],[466],"focused ultrasound","2026-02-06",{"date":469,"type":35},"2026-02-10",{"date":471,"type":35},"2021-07-26",{"date":473,"type":22},"2027-12",{"name":475,"class":99},"University of California, Los Angeles",3,{"id":478,"slug":479,"hasResults":12,"nctId":480,"briefTitle":481,"officialTitle":482,"acronym":4,"eligibilityCriteria":483,"healthyVolunteers":75,"sex":17,"minAge":18,"maxAge":293,"enrollmentInfo":484,"targetDuration":4,"studyType":23,"phases":486,"briefSummary":487,"conditions":488,"keywords":489,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":498,"locationsCount":4},"100623131","electroacupuncture-for-generalized-anxiety-disorder-clinical-efficacy-and-neuroimaging-mechanisms-100623131","NCT07392645","Electroacupuncture for Generalized Anxiety Disorder: Clinical Efficacy and Neuroimaging Mechanisms","Clinical Efficacy of Electroacupuncture for Generalized Anxiety Disorder and Its Central Mechanism Based on Neuroimaging Changes","Inclusion Criteria:\n\n* Meet the DSM-5 diagnostic criteria for Generalized Anxiety Disorder (GAD).\n* No antidepressant or anti-anxiety medication in the past 2 weeks.\n* HAMA score ≥ 14.\n* Right-handed（for MRI).\n* Aged 18-60 years, with at least primary school education.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Complicated with severe cardiovascular, cerebrovascular, or organic diseases.\n* History of other psychiatric disorders (e.g., schizophrenia, bipolar disorder).\n* Contraindications for MRI (e.g., metal implants, claustrophobia).\n* Pregnancy or lactation.",{"count":485,"type":22},123,[111],"This study aims to evaluate the clinical efficacy and safety of electroacupuncture (EA) in treating Generalized Anxiety Disorder (GAD). Participants will be randomly assigned to an EA group, a sham EA group, or a waiting-list control group. All participants will continue their routine medication (Paroxetine). The primary goal is to observe the reduction in anxiety symptoms using the Hamilton Anxiety Scale (HAMA). Additionally, the study will use functional MRI (fMRI) and Magnetic Resonance Spectroscopy (MRS) to explore the brain mechanisms through which EA helps alleviate anxiety.",[28],[490,28,491,492],"Electroacupuncture","fMRI","Clinical Efficacy","2026-02-05",{"date":467,"type":35},{"date":496,"type":22},"2026-02-01",{"date":171,"type":22},{"name":499,"class":99},"Lishu Gao",{"id":501,"slug":502,"hasResults":12,"nctId":503,"briefTitle":504,"officialTitle":505,"acronym":506,"eligibilityCriteria":507,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":293,"enrollmentInfo":508,"targetDuration":4,"studyType":23,"phases":510,"briefSummary":511,"conditions":512,"keywords":513,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":527,"locationsCount":66},"100623973","mapsd-dual-target-ctbs-auditory-cortex-and-m1-for-generalized-anxiety-disorder-100623973","NCT07403591","Mapsd Dual-target cTBS (Auditory Cortex and M1) for Generalized Anxiety Disorder","Efficacy and Neural Mechanisms of Neuroimage-guided Dual-target Continuous Theta Burst Stimulation (Auditory Cortex and M1) for Generalized Anxiety Disorder","Dual-ACM1-GAD","Inclusion Criteria:\n\n1. Diagnosis of Generalized Anxiety Disorder (GAD) according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), confirmed by at least two psychiatrists.\n2. Hamilton Anxiety Rating Scale (HAMA) score \\> 14.\n3. Age between 18 and 60 years.\n4. Right-handed.\n5. More than 5 years of education.\n6. Patients are either medication-free or maintain a consistent medication regimen during cTBS treatment.\n7. Willing and able to provide written informed consent.\n8. Normal or corrected-to-normal visual acuity and hearing.\n\nExclusion Criteria:\n\n1. Presence of other psychiatric disorders, such as substance abuse, schizophrenia, schizoaffective disorder, hysteria, autism, or bipolar disorder.\n2. History of epilepsy, seizures, or severe neurological diseases (e.g., stroke, organic brain lesions).\n3. Presence of severe somatic diseases, such as severe heart, liver, or renal insufficiency.\n4. Pregnant or lactating women.\n5. Contraindications to Transcranial Magnetic Stimulation (TMS) or Magnetic Resonance Imaging (MRI), such as the presence of a cardiac pacemaker, cochlear implant, cerebrovascular metal stent, or metal dentures.\n6. Inability to cooperate with experimental procedures due to conditions such as severe claustrophobia.",{"count":509,"type":22},60,[111],"The purpose of this study is to investigate the effectiveness of a dual-target non-invasive brain stimulation technique called continuous Theta Burst Stimulation (cTBS) for treating Generalized Anxiety Disorder (GAD). The researchers will use a neuronavigation system, which acts like a GPS for the brain, to guide the stimulation to two specific targets: the left auditory association cortex and the primary motor cortex (M1).\n\nParticipants will be randomly assigned to one of two groups. One group will receive active dual-target cTBS treatment, while the other will receive a sham (placebo) stimulation that feels similar but has no therapeutic effect. The treatment will be given three times a day for seven consecutive days. Before and after the treatment period, all participants will complete clinical questionnaires to measure their anxiety and undergo Magnetic Resonance Imaging (MRI) scans to help researchers understand how cTBS affects brain activity.",[28],[28,514,515,516,517,518,519],"Continuous Theta Burst Stimulation","Transcranial Magnetic Stimulation","Neuronavigation","Dual-target","Auditory Cortex","Primary Motor Cortex","2026-02-04",{"date":522,"type":35},"2026-02-11",{"date":524,"type":22},"2026-03-01",{"date":526,"type":22},"2027-04-01",{"name":528,"class":99},"Anhui Medical University",{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":4,"eligibilityCriteria":535,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":536,"enrollmentInfo":537,"targetDuration":4,"studyType":23,"phases":539,"briefSummary":540,"conditions":541,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":542,"startDateStruct":543,"completionDateStruct":545,"leadSponsor":547,"locationsCount":66},"100444237","mbsr-mechanisms-in-gad-100444237","NCT05064813","MBSR Mechanisms in GAD","Elucidating Neural Mechanisms and Sex Differences in Response to Mindfulness Based Stress Reduction in Generalized Anxiety Disorder","Inclusion Criteria:\n\n* Male or pre-menopausal female outpatients aged 18 to 50 years of age\n* A primary mental health complaint (designated by the patient as the most important source of current distress and confirmed on structured clinical interview for DSM-5 diagnoses by a certified clinical evaluator) of Generalized Anxiety Disorder (GAD), as defined by DSM-5 criteria.\n* Overall clinical anxiety severity of at least mild as defined by a CGI-S of at least 3.\n* Willingness and ability to participate in the informed consent process and comply with the requirements of the study protocol.\n\nExclusion Criteria:\n\n* A lifetime history of bipolar disorder, schizophrenia, psychosis, or delusional disorders; obsessive-compulsive disorder or an eating disorder in the past 12 months; neurocognitive disorders, intellectual disabilities, communication disorders or other cognitive dysfunction that could interfere with capacity to engage in therapy or complete study procedures; substance or alcohol use disorder (other than nicotine) in the last 6 months or otherwise unable to commit to refraining from alcohol use during the acute period of study participation.\n* Patients with significant suicidal ideation (assessed by CSSR-S SI score greater than 2) or who have enacted suicidal behaviors within 6 months prior to intake will be excluded from study participation and referred for appropriate clinical intervention.\n* Patients must be free of concurrent benzodiazepine, antipsychotic, and stimulant medication for at least 4 weeks prior to initiation of randomized treatment. Other psychiatric medications such as antidepressants that have been stable for at least 4 weeks prior to randomization will be permitted.\n* Inability to understand study procedures or informed consent process, or significant personality dysfunction likely to interfere with study participation (assessed during the clinical interview) or inability to comply with study procedures (such as planned extended travel) assessed on clinical interview\n* Serious current unstable medical illness, or a condition for which hospitalization may be likely within the next year as assessed by medical history and physical exam. If any questions about medical safety emerge, consent will be formally obtained to contact patient's PCP in order to determine whether any medical concerns making participation unsafe or not feasible (such as need for extended inpatient care) are present; MBSR and SE, however, do not require intensive exercise capacity or mobility.\n* Pregnant women (to be ruled out by urine ß-HCG) and women of childbearing potential who are not using medically accepted forms of contraception (such as IUD, oral contraceptives, barrier devices, condoms and foam, or implanted progesterone rods stabilized for at least 3 months).\n* Any concurrent psychotherapy initiated within 3 months of baseline, or ongoing psychotherapy of any duration directed specifically toward treatment of GAD or with any mindfulness and\u002For meditation component is excluded. Prohibited psychotherapy includes CBT, DBT, ACT, mindfulness based approaches, or psychodynamic therapy focusing on exploring specific, dynamic causes of the GAD symptomatology and providing management skills. General supportive therapy initiated greater than 3 months prior is acceptable.\n* Individuals who have completed a course of MBSR or an equivalent meditation training or who have an ongoing regular meditation practice in the past 2 years.\n* Patients with a history of head trauma causing loss of consciousness, seizure or ongoing cognitive impairment.\n* Contraindications for MRI including metal implants, surgical clips, probability of metal fragments, or braces that are prohibited due to severe risk of injury.\n* Left handed","50 Years",{"count":538,"type":22},150,[111],"The purpose of this study is to understand the neural mechanisms that drive response to MBSR compared to stress education in patients with generalized anxiety disorder (GAD), and to examine the degree to which sex differences in MBSR response are explained by sex differences in these mechanisms. A total of 150 eligible participants with a primary diagnosis of GAD will be randomized to either an 8-week group MBSR or stress education program. The study will include preliminary screening, experimental visits, including fMRI, group intervention visits, and assessments at baseline, endpoint, and 3-month follow-up.",[28],{"date":467,"type":35},{"date":544,"type":35},"2021-11-18",{"date":546,"type":22},"2026-06-30",{"name":548,"class":99},"NYU Langone Health",{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":554,"acronym":4,"eligibilityCriteria":555,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":556,"targetDuration":4,"studyType":23,"phases":557,"briefSummary":558,"conditions":559,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":563,"completionDateStruct":565,"leadSponsor":566,"locationsCount":4},"100622338","metacognitive-therapy-compared-to-cognitive-behavioral-therapy-100622338","NCT07382323","Metacognitive Therapy Compared to Cognitive-behavioral Therapy","Transdiagnostic Metacognitive Therapy Compared to Disorder-specific Cognitive-behavioral Therapy for Anxiety Disorders: a Qualitative Study","Inclusion Criteria:\n\n* Age 18 years or older,\n* A principal diagnosis of generalized anxiety disorder, social anxiety disorder, or posttraumatic stress disorder,\n* No change in dose during the last six weeks if on pharmacological treatment, and\n* Ability to read and speak Swedish.\n\nExclusion Criteria:\n\n* A current diagnosis of psychotic disorder, bipolar disorder, neurocognitive disorder, or moderate to severe substance use disorder,\n* Acute suicide risk, or\n* Concurrent psychological treatment.",{"count":261,"type":22},[111],"This is a qualitative study of participants who have taken part in a randomized controlled trial comparing transdiagnostic metacognitive therapy and disorder-specific cognitive-behavioral therapy for anxiety disorders. The purpose of the study is to explore participant perceptions of the respective treatment models to facilitate implementation and dissemination of the treatments.",[28,116,560],"Posttraumatic Stress Disorder (PTSD)","2026-02-02",{"date":520,"type":35},{"date":564,"type":22},"2026-02",{"date":347,"type":22},{"name":567,"class":99},"Karolinska Institutet",{"id":569,"slug":570,"hasResults":12,"nctId":571,"briefTitle":572,"officialTitle":573,"acronym":4,"eligibilityCriteria":574,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":575,"targetDuration":4,"studyType":23,"phases":577,"briefSummary":578,"conditions":579,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":580,"lastUpdatePostDateStruct":581,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":587,"locationsCount":509},"100570027","phase-2-study-of-iti-1284-as-monotherapy-treatment-in-patients-with-generalized-anxiety-disorder-100570027","NCT06701903","Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder","A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment","Inclusion Criteria:\n\n* Provide written informed consent before the initiation of any study specific procedures;\n* At Screening, meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) diagnostic criteria for moderate or severe GAD as confirmed by the Investigator or Sponsor-approved rater using the Structured Clinical Interview for DSM-5 Clinical Trials Version (SCID-5-CT), and meets all of the following at Screening and Baseline:\n\n  * HAM-A Total score of ≥ 22;\n  * HAM-A Items 1 (anxious mood) and 2 (tension) scores ≥ 2;\n  * CGI-S score of ≥ 4;\n* History of inadequate response (\\\u003C 50% improvement in anxiety symptoms as measured by the modified Antidepressant Treatment Response Questionnaire \\[ATRQ\\] for GAD) to at least 2 of the following GAD-approved treatments: paroxetine, venlafaxine XR, duloxetine, escitalopram, or buspirone taken at an adequate dose (at least the minimum GAD-approved dose per package insert) and duration (ie, for at least 6 weeks prior to Screening) for the treatment of ongoing GAD symptoms.\n\nExclusion Criteria:\n\n* Within the patient's lifetime, has one of the following confirmed DSM-5-TR psychiatric diagnoses:\n\n  * Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder or other psychotic disorder;\n  * Bipolar Disorder;\n* MADRS total score \\> 18 at Screening or Baseline;\n* In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during his\u002Fher participation in the study or\n\n  * At Screening, the patient scores \"yes\" on Suicidal Ideation Items 4 or 5 of the C-SSRS within 6 months prior to Screening or, at Baseline, the patient scores \"yes\" on Suicidal Ideation Items 4 or 5 since the Screening Visit;\n  * At Screening, the patient has had 1 or more suicidal attempts within the 2 years prior to Screening;\n  * At Screening or Baseline MADRS Item 10 score ≥ 5; or\n  * The patient is considered to be an imminent danger to him\u002Fherself or others based on the assessment of the Investigator;\n* Lifetime history of failure to respond to \\> 3 of the approved treatments for GAD (ie, paroxetine, venlafaxine XR, duloxetine, escitalopram, or buspirone) at an adequate dose (ie, at least the minimum dose approved for GAD per package insert) and for an adequate duration (ie, at least 6 weeks).",{"count":576,"type":22},570,[25],"This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of ITI-1284 as monotherapy treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD in patients who have had inadequate response to generalized anxiety disorder treatment.",[28],"2026-01-07",{"date":582,"type":35},"2026-01-09",{"date":584,"type":35},"2024-11-21",{"date":586,"type":22},"2027-06",{"name":588,"class":42},"Intra-Cellular Therapies, Inc.",{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":573,"acronym":4,"eligibilityCriteria":594,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":595,"targetDuration":4,"studyType":23,"phases":597,"briefSummary":598,"conditions":599,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":580,"lastUpdatePostDateStruct":600,"startDateStruct":601,"completionDateStruct":603,"leadSponsor":604,"locationsCount":605},"100552999","phase-2-study-of-iti-1284-as-an-adjunctive-treatment-in-patients-with-generalized-anxiety-disorder-100552999","NCT06480383","Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder","Inclusion Criteria:\n\n1. Provide written informed consent before the initiation of any study specific procedures;\n2. Male or female patients ≥ 18 years of age;\n3. At Screening, meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) diagnostic criteria for moderate or severe GAD as confirmed by the Investigator or Sponsor-approved rater using the Structured Clinical Interview for DSM-5 Clinical Trials Version (SCID-5-CT), and meets all of the following at Screening and Baseline:\n\n   1. HAM-A Total score of ≥ 22;\n   2. HAM-A Items 1 (anxious mood) and 2 (tension) scores ≥ 2;\n   3. CGI-S score of ≥ 4;\n4. History of inadequate response (\\\u003C 50% improvement in anxiety symptoms as measured by the modified Antidepressant Treatment Response Questionnaire \\[ATRQ\\] for GAD) to at least 1 GAD-approved treatment (ie, one of the following GAD-approved treatments: paroxetine, venlafaxine XR, duloxetine, escitalopram, or buspirone) taken at an adequate dose (at least the minimum GAD-approved dose per package insert) and duration (ie, daily for at least 6 weeks) for the treatment of ongoing GAD symptoms;\n5. Currently having an inadequate response to one of the following GAD-approved treatments: paroxetine, venlafaxine XR, duloxetine, escitalopram, or buspirone taken at an adequate dose (at least the minimum GAD-approved dose per package insert) and duration (ie, for at least 6 weeks prior to Screening) and agrees to continue the same dosing regimen for the duration of the study.\n\nNOTE: The current GAD-approved treatment must be different from the GAD treatment identified as the historical failure.\n\nExclusion Criteria:\n\n1. Within the patient's lifetime, has one of the following confirmed DSM-5-TR psychiatric diagnoses:\n\n   1. Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder or other psychotic disorder;\n   2. Bipolar Disorder;\n2. MADRS total score \\> 18 at Screening or Baseline;\n3. In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during his\u002Fher participation in the study or\n\n   1. At Screening, the patient scores \"yes\" on Suicidal Ideation Items 4 or 5 of the C-SSRS within 6 months prior to Screening or, at Baseline, the patient scores \"yes\" on Suicidal Ideation Items 4 or 5 since the Screening Visit;\n   2. At Screening, the patient has had 1 or more suicidal attempts within the 2 years prior to Screening;\n   3. At Screening or Baseline MADRS Item 10 score ≥ 5; or\n   4. The patient is considered to be an imminent danger to him\u002Fherself or others based on the assessment of the Investigator.\n4. Lifetime history of failure to respond to \\> 3 of the approved treatments for GAD (ie, paroxetine, venlafaxine XR, duloxetine, escitalopram, or buspirone) at an adequate dose (ie, at least the minimum dose approved for GAD per package insert) and for an adequate duration (ie, at least 6 weeks).",{"count":596,"type":22},705,[25],"This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo as adjunctive therapy to GAD treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD who have an inadequate response to ongoing GAD treatment.",[28],{"date":582,"type":35},{"date":602,"type":35},"2024-08-05",{"date":586,"type":22},{"name":588,"class":42},69,{"id":607,"slug":608,"hasResults":12,"nctId":609,"briefTitle":610,"officialTitle":611,"acronym":612,"eligibilityCriteria":613,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":614,"targetDuration":4,"studyType":23,"phases":616,"briefSummary":617,"conditions":618,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":619,"lastUpdatePostDateStruct":620,"startDateStruct":621,"completionDateStruct":623,"leadSponsor":624,"locationsCount":66},"100618363","phase-2-prospective-clinical-trial-of-crisugabalin-capsules-in-the-treatment-of-generalized-anxiety-disorder-100618363","NCT07330648","Prospective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder","Evaluation of the Efficacy and Safety of Crisugabalin Capsules Versus Placebo and Venlafaxine Extended-Release (XR) Capsules in Chinese Patients With Generalized Anxiety Disorder: A Prospective, Multicenter, Randomized, Double-Blind, Double-Dummy, Active- and Placebo-Controlled Clinical Trial.","CEASE-GAD","Inclusion Criteria:\n\n* Able to understand and voluntarily participate in the trial, and provide written informed consent form (ICF);\n* Male or female aged ≥18 years (inclusive of the threshold value);\n* Met the diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for generalized anxiety disorder (GAD) and confirmed by the Brief International Neuropsychiatric Interview (M.I.N.I.);\n* Require pharmacological treatment for psychiatric symptoms;\n* Hamilton Anxiety Scale (HAMA) score ≥20, Hamilton Depression Scale (HAMD-17) score ≤2, Clinical Global Impression Scale (CGI-S) score ≥4 at screening and baseline Points;\n\nExclusion Criteria:\n\n* subjects with serious suicide risk at present, or HAMD-17 item 3-suicide score ≥3;\n* subjects with HAMD-17 \\> 17;\n* subjects whose HAMA scores decreased by ≥20% in the baseline period compared with the screening period:\n* Those who met the DSM-5 diagnostic criteria for other mental disorders except GAD;\n* subjects with previous history of depression, obsessive-compulsive disorder, bipolar disorder, psychotic disorder, factitious disorder and somatoform disorder; There were severe personality disorders, especially antisocial, borderline, or histrionic personality disorder, which were judged by the investigator to affect the patient's adherence to the study protocol;\n* Alcohol or drug abuse or dependence within 180 days before screening;\n* With severe or unstable has clinical significance of somatic disease, including any cardiovascular, cancer, kidney, respiratory, endocrine (including abnormal thyroid function), digestion, blood (such as with bleeding tendency) or nervous system diseases;\n* History of inadequate response to at least two prior antidepressant drugs and\u002For benzodiazepines after adequate dose and duration of treatment (i.e., at least 4 weeks at a clinically appropriate dose), or failure to achieve sufficient clinical efficacy with pregabalin ≥300 mg\u002Fday (i.e., subject-reported insufficient response or lack of meaningful clinical improvement).\n* History of severe hypersensitivity reactions (e.g., anaphylaxis) or allergies to at least two classes of drugs (including photosensitivity), or known hypersensitivity to pregabalin, the investigational drug, structurally related compounds, or any of their excipients.\n* subjects whose physical examination or vital signs were abnormal and clinically significant (e.g. inadequately controlled hypertension, systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg);\n* subjects with a history of epilepsy or any other disease that may induce seizures, except convulsions caused by febrile convulsions in children;\n* Severe hematologic, hepatic or renal dysfunction during the screening period, the subject will be excluded if: a. Neutrophils \\\u003C 1.5 × 10\\^9\u002FL, or platelet \\\u003C 90 × 10\\^9\u002FL, or hemoglobin \\\u003C 100 g\u002FL; b. AST\u002FALT \\> 2.5 × upper limit of normal (ULN), or TBIL \\> 1.5 × ULN; c. Estimation of glomerular filtration rate (eGFR) \\\u003C 60 mL\u002Fmin \u002F 1.73 m\\^2; d. Creatine kinase \\> 2.0 × ULN.\n* Clinically significant abnormalities on electrocardiography (QT interval corrected by Fridericia method: ≥450 ms for men or ≥470 ms for women) or conditions deemed ineligible by the investigators;\n* Subjects who had undergone psychiatric surgery, electroconvulsive therapy or transcranial magnetic stimulation within 90 days before screening;\n* Use of β-blockers within 90 days prior to screening with an ongoing need for continued treatment;\n* Receiving systemic psychotherapy or other non-pharmacological treatments (e.g., acupuncture, hypnosis, or phototherapy) within 6 weeks before the baseline visit;\n* Subjects with dysphagia or inability to tolerate oral medications.\n* Subjects with active gastrointestinal disorders (including any history of gastrointestinal surgery) that, in the investigator's judgment, may interfere with the absorption of the investigational drug.\n* Those who had used benzodiazepines within -7 to -1 days before screening, such as lorazepam, oxazepam, and alprazolam for less than 5 half-lives; The use of benzodiazepines with longer half-lives, such as diazepam, clonazepam, nitrazepam, estazolam, and flurazepam, not more than 5 half-lives or less than 30 days from the screening period, or the use of barbiturates not more than 5 half-lives or less than 30 days from the screening period;\n* Patients who discontinued traditional Chinese medicine, melatonin, and St. John's wort for less than 3 days before the baseline visit;\n* Pregnant or preparing for pregnancy or breastfeeding during the study period, or subjects were not willing to use reliable contraceptives methods from the date of ICF signature until 28 days after the last trial drug administration, or planning to use progesterone contraceptives during this period;\n* Individuals engaged in potentially hazardous mechanical operations such as working at heights or operating motor vehicles.\n* Participants enrolled in other clinical trials within 30 days before screening;\n* Subjects with other conditions deemed by the investigator to be ineligible for enrollment.",{"count":615,"type":22},216,[25],"A placebo-controlled superiority design was used to evaluate the efficacy of 40 mg\u002F day of Crisugabalin capsules in the treatment of GAD.",[28],"2025-12-29",{"date":582,"type":35},{"date":622,"type":35},"2025-10-10",{"date":124,"type":22},{"name":528,"class":99},{"id":626,"slug":627,"hasResults":12,"nctId":628,"briefTitle":629,"officialTitle":630,"acronym":631,"eligibilityCriteria":632,"healthyVolunteers":75,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":633,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":635,"conditions":636,"keywords":639,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":642,"lastUpdatePostDateStruct":643,"startDateStruct":645,"completionDateStruct":647,"leadSponsor":649,"locationsCount":66},"100616445","cohort-study-on-medical-students-mental-health-100616445","NCT07305701","Cohort Study on Medical Students' Mental Health","Mental Health of Medical Students in Orleans: a Cohort Study of a New Faculty","OSMOSE","Inclusion Criteria:\n\n* Students who have been enrolled in first year of health studies at the University of Orléans\n* Aged 18 or over\n\nExclusion Criteria:\n\n* Does not speak French\n* Person under legal guardianship\n* Person deprived of liberty\n* Person under guardianship or trusteeship",{"count":634,"type":22},10000,"The main objective of this study is to identify risk factors for depression among medical students by comparing them to students who completed their first year but did not enter the medical program (students not accepted into the second year of medical school).\n\nMajor Depressive Disorder (MDD) will be assessed using a validated tool: the Composite International Diagnostic Interview Short-Form (CIDI-SF).\n\nThis a prospective, longitudinal, cohort study. The plan is to inform each new cohort of students at the Orléans University Hospital medical school for 10 years. It is estimated that 5,000 to 10,000 students will be able to participate in the study.\n\nA link to access the study questionnaire will be sent to students by email via the registrar's office, with one email per week for four weeks. The email will contain a link to a web page where the questionnaire can be completed. The questionnaire will be available online on computers or smartphones for six weeks: from mid-October to the end of November. The questionnaire will be completed each year for the duration of the study or until the student completes their studies.\n\nDuration of the inclusion period: 10 years Duration of participation for each participant: maximum 12 years Total duration of the study: 22 years As the cohort progresses, longitudinal analyses may be conducted to study the evolution of various disorders over time, adjusting for known confounding factors. Following the initial analyses of this study, a new interventional study will be set up to identify students at risk and offer them appropriate care.",[163,28,82,637,638,83],"Alcoholism","Marijuana Abuse",[85,640,431,641],"Medical students","epidemiology","2025-12-26",{"date":644,"type":35},"2025-12-31",{"date":646,"type":35},"2025-10-22",{"date":648,"type":22},"2047-10-31",{"name":650,"class":99},"Centre Hospitalier Régional d'Orléans",{"id":652,"slug":653,"hasResults":12,"nctId":654,"briefTitle":655,"officialTitle":656,"acronym":657,"eligibilityCriteria":658,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":259,"enrollmentInfo":659,"targetDuration":4,"studyType":23,"phases":661,"briefSummary":662,"conditions":663,"keywords":669,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":675,"lastUpdatePostDateStruct":676,"startDateStruct":678,"completionDateStruct":679,"leadSponsor":681,"locationsCount":127},"100585999","ultra-brief-psychological-treatments-for-emotional-symptoms-and-disorders-100585999","NCT06909669","Ultra-brief Psychological Treatments for Emotional Symptoms and Disorders","Ultra-brief Psychological Treatments for Emocional Symptoms and Disorders: An Efficacy and Efficiency Analysis","UltraPsyBrief","Inclusion Criteria:\n\n\\- Patients presenting negative emotional symptomatology (anxiety, depression or somatizations), mild or moderate. Specifically, they will be included in the study if they present a score ≥ 5 on the PHQ-9, the GAD-7 or the PHQ-15.\n\nExclusion Criteria:\n\n* Bipolar disorder, personality disorder, psychosis or substance abuse, indicated by SCID-5-CV\n* Recent suicide attempt.\n* Severe emotional symptoms (PHQ-15 or GAD-7 ≥ 15; or PHQ-9 ≥ 20).",{"count":660,"type":22},184,[111],"The main objective of this randomized clinical trial is to study if various modalities of brief (eight sessions) and ultra-brief (four sessions) transdiagnostic cognitive-behavioral treatment work for decrease emotional symptoms and disorders, as well as to find out which variables of cognition and of the intervention process itself are involved in the therapeutic improvement.\n\nThe investigators will compare the interventions of four groups: brief group treatment (1), ultra-brief group treatment (2), ultra-brief individual treatment (3) with the ultra-brief relaxation (control) group.\n\nThe main questions the study aims to answer are:\n\n* Will the brief and ultra-brief treatment formats works better than the relaxation-based control group?\n* Will results obtained between the brief group therapy group and the ultra-brief group therapy group be similar?\n* Will the individual ultra brief therapy be more effective than the two group therapies because of common factors, such as the therapeutic alliance?\n* Will group therapies be more beneficial for cost and in terms of capability to reduce emocional symptoms than individual therapy? Participants will be randomly assigned to each of the groups and will receive the corresponding treatment, with different number of sessions. They will answer a series of questionnaires at the beginning and at the end of the intervention, as well as 3 months and 6 months after the end of the treatment.",[664,28,196,140,665,666,667,668],"Depression - Major Depressive Disorder","Somatoform Disorders","Somatic Symptom Disorder (DSM-5)","Somatization","Emotional Disorders",[670,671,672,673,674],"ultra-brief therapy","brief therapy","transdiagnostic therapy","cognitive-behavioral therapy","randomized controled trial","2025-12-15",{"date":677,"type":35},"2025-12-22",{"date":564,"type":22},{"date":680,"type":22},"2028-09",{"name":682,"class":99},"Universidad de Córdoba"]